NeuroVive Pharmaceutical AB Product Size & Share - 2015

1
NeuroVive Pharmaceutical AB Product Pipeline
Review - 2015
Published on October - 2015
2
.
Report Overview
About NeuroVive Pharmaceutical AB Product
Pipeline Review 2015 Global Markets Directs,
NeuroVive Pharmaceutical AB Product Pipeline
Review - 2015, provides an overview of the
NeuroVive Pharmaceutical AB s pharmaceutical
research and development focus. This report
provides comprehensive information on the current
therapeutic developmental pipeline of NeuroVive
Pharmaceutical AB s, complete with comparative
analysis at various stages, therapeutics
assessment by drug target, mechanism of action
(MoA), route of administration (RoA) and molecule
type. It also reviews latest updates, and
featured news and press releases, along with
special features on late-stage and discontinued
projects. Global Markets Directs report features
investigational drugs from across globe covering
over 20 therapy areas and nearly 3,000
indications. The report is built using data and
information sourced from Global Markets Directs
proprietary databases, Company/University
websites, SEC filings, investor presentations and
featured press releases from company/university
sites and industry-specific third party sources,
put together by Global Markets Directs team. Get
Full Details On http//www.researchbeam.com/neur
ovive-pharmaceutical-ab-product-pipeline-review-20
15-market
3
.
Report Overview
Drug profiles/records featured in the report
undergoes periodic updation following a stringent
set of processes that ensures that all the
profiles are updated with the latest set of
information. Additionally, processes including
live news deals tracking, browser based
alert-box and clinical trials registries tracking
ensure that the most recent developments are
captured on a real time basis. The report
enhances decision making capabilities and help to
create effective counter strategies to gain
competitive advantage. It strengthens RD
pipelines by identifying new targets and MOAs to
produce first-in-class and best-in-class
products. Note Certain sections in the report
may be removed or altered based on the
availability and relevance of data for the
indicated disease. Scope The report provides
brief overview of NeuroVive Pharmaceutical AB
including business description, key information
and facts, and its locations and subsidiaries The
report reviews current pipeline of NeuroVive
Pharmaceutical ABs human therapeutic division and
enlists all their major and minor projects
4
.
Report Overview
The report features product description and
descriptive mechanism of action for key pipeline
products along with the products developmental
history and major milestones Special feature on
out-licensed and partnered product portfolio The
report summarizes all the dormant and
discontinued pipeline projects Latest company
statement Latest news and deals relating to the
NeuroVive Pharmaceutical ABs pipeline
products   Reasons to buy Evaluate NeuroVive
Pharmaceutical ABs strategic position with total
access to detailed information on its product
pipeline Assess the growth potential of NeuroVive
Pharmaceutical AB in its therapy areas of
focus Identify new drug targets and therapeutic
classes in the NeuroVive Pharmaceutical ABs RD
portfolio and develop key strategic initiatives
to reinforce pipeline in those areas Exploit
in-licensing opportunities by identifying windows
of opportunity to fill portfolio gaps
5
Report Overview

• Develop strategic initiatives by understanding
  the focus areas of NeuroVive Pharmaceutical AB
  and exploit collaboration and partnership
  opportunities
• Identify emerging players with potentially strong
  product portfolio and create effective
  counter-strategies to gain competitive advantage
• Plan mergers and acquisitions effectively by
  identifying the most promising pipeline of
  NeuroVive Pharmaceutical AB
• Develop and design in-licensing and out-licensing
  strategies by identifying prospective partners
  with the most attractive projects to enhance and
  expand business potential and Scope
• Explore the dormant and discontinued projects of
  NeuroVive Pharmaceutical AB and identify
  potential opportunities in those areas
• Avoid Intellectual Property Rights related issues

6
Table Of Contents
List of Tables 5List of Figures 5NeuroVive
Pharmaceutical AB Snapshot 6NeuroVive
Pharmaceutical AB Overview 6Key Information
6Key Facts 6NeuroVive Pharmaceutical AB -
Research and Development Overview 7Key
Therapeutic Areas 7NeuroVive Pharmaceutical AB
- Pipeline Review 10Pipeline Products by Stage
of Development 10Pipeline Products - Monotherapy
11Pipeline Products - Partnered Products
12Partnered Products/Combination Treatment
Modalities 13Pipeline Products - Out-Licensed
Products 14
7
Table Of Contents
Out-Licensed Products/Combination Treatment
Modalities 15NeuroVive Pharmaceutical AB -
Pipeline Products Glance 16NeuroVive
Pharmaceutical AB - Clinical Stage Pipeline
Products 16Phase II Products/Combination
Treatment Modalities 16Phase I
Products/Combination Treatment Modalities
17NeuroVive Pharmaceutical AB - Early Stage
Pipeline Products 18Preclinical
Products/Combination Treatment Modalities
18Discovery Products/Combination Treatment
Modalities 19NeuroVive Pharmaceutical AB - Drug
Profiles 20
8
Table Of Contents
CV-9103 20Product Description 20Mechanism of
Action 20RD Progress 20 CV-9104 22Product
Description 22Mechanism of Action 22RD
Progress 22   Enquiry about this report _at_
http//www.researchbeam.com/neurovive-pharmaceutic
al-ab-product-pipeline-review-2015-market/enquire-
about-report
9
FOR MORE DETAILS
Visit us at
http//www.researchbeam.com/neurovive-pharmaceutic
al-ab-product-pipeline-review-2015-market
Stay With Us
5933 NE Win Sivers Drive,205, Portland, OR
97220United States
TELEPHONE [phone] E-MAIL
sales_at_researchbeam.com